AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04734756 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dragonfly Transcatheter Mitral Valve Repair System
Description: To conduct edge-to-edge repair with Dragonfly System under the guidance of transesophageal echocardiography.
Study NCT05126823 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and commitment therapy + app
Description: In the group ACT+app, experiential exercises are carried out, metaphors, discussions and assignments are used to promote awareness and flexibility about the thoughts and emotions associated with cancer and interleaved non-contact activities, which will serve as support for each of the modules. The non-contact activities will consist of assigning tasks, practices (mindfulness, breathing), reminder systems, recording, reinforcement and monitoring. Resources such as short texts, videos, audio files and recording systems will be used
Study NCT05126823 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Acceptance and commitment therapy
Description: In the group ACT, experiential exercises are carried out, metaphors, discussions and assignments are used to promote awareness and flexibility about the thoughts and emotions associated with cancer
Study NCT06440304 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosfomycin
Description: Patients will be randomly divided according to a predetermined randomization table Upon arrival of a positive microbiological finding on A. baumannii, patient will be randomised to one of groups (Colistin with Unasyn OR Colistin with Xerava OR Colistin with Fosfomycin
Study NCT06440304 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eravacycline
Description: Patients will be randomly divided according to a predetermined randomization table Upon arrival of a positive microbiological finding on A. baumannii, patient will be randomised to one of groups (Colistin with Unasyn OR Colistin with Xerava OR Colistin with Fosfomycin
Study NCT06440304 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ampicillin/sulbactam
Description: Patients will be randomly divided according to a predetermined randomization table Upon arrival of a positive microbiological finding on A. baumannii, patient will be randomised to one of groups (Colistin with Unasyn OR Colistin with Xerava OR Colistin with Fosfomycin
Study NCT04770168 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy Curriculum
Description: The 3-month Harry Potter curriculum is delivered by trained teachers and includes lessons on a) risk factors that can contribute to emotional distress, b) how depression and anxiety manifest and how to access support/treatment, c) cognitive distortions, how they differ from rational thoughts and basic cognitive restructuring techniques, d) crisis planning including personalized stressbusters and hope kits, and e) how to be resilient.
Study NCT05727566 — intervention group
Intervention type: OTHER
Intervention: visual pain scale (VASpain/fatigue), Beck depression index (BDI), the sexuality-importance score, sexual intercourse frequency
Description: visual pain scale (VASpain/fatigue), Beck depression index (BDI), the sexuality-importance score, sexual intercourse frequency
Study NCT06483100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elrantamab
Description: - Elranatamab will be dosed in 28-day cycles as follows:~* C1D1: 12 mg SC priming dose~* C1D4: 32 mg SC priming dose~* C1D8, C1D15, C1D22: 76 mg SC~* Cycle 2 and all subsequent cycles: 76 mg SC on D1 and D15
Study NCT06483100 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: clonoSEQ
Description: FDA approved MRD testing
Study NCT05433103 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-Load Exercise with Blood Flow Restriction
Description: Participants in the BFR group will attend a 10-week, twice weekly intervention exercise session combining low-load resistance training with at least 60% blood flow occlusion. Standard education regarding the importance of exercise for people with MS will also be provided. All participants will also be asked to practice a home exercise program focusing on functional tasks one time a week.
Study NCT05527314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: Anesthesia was induced with Remimazolam 0.4-0.8 mg/kg (about 1 minute) by intravenous injection until the loss of consciousness (LoC), followed by remimazolam 1-2 mg/kg/h until the end of surgery.
Study NCT05433103 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-Load Exercise Control Group
Description: Participants in the Control group will attend a 10-week, twice weekly intervention exercise session combining low-load resistance training. Standard education regarding the importance of exercise for people with MS will also be provided. All participants will also be asked to practice a home exercise program focusing on functional tasks one time a week.
Study NCT05527314 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Anesthesia was induced with 8 % Sevoflorane by sevoflurane volatilization tank until the loss of consciousness (LoC), followed by 2 %-3 % Sevoflorane until the end of surgery.
Study NCT05527314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Anesthesia was induced with fentanyl 3-4 ug/kg by intravenous injection after the LoC.
Study NCT05980052 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Theory-driven behavioral physical activity promotion intervention.
Study NCT05527314 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Anesthesia was induced with fentanyl 3-4 ug/kg by intravenous injection after the LoC.
Study NCT05527314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisatracurium Besylate
Description: Anesthesia was induced with cisatracurium besilate 0.1 mg/kg by intravenous injection after the LoC. And the cisatracurium besilate 0.02 mg/kg is allowed to add as appropriate during the operation.
Study NCT05527314 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisatracurium Besylate
Description: Anesthesia was induced with cisatracurium besilate 0.1 mg/kg by intravenous injection after the LoC. And the cisatracurium besilate 0.02 mg/kg is allowed to add as appropriate during the operation.
Study NCT05527314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: After the LoC, remifentanil 0.1\~0.3 ug/kg/min inject intravenously until the end of surgery.
Study NCT05527314 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: After the LoC, remifentanil 0.1\~0.3 ug/kg/min inject intravenously until the end of surgery.
Study NCT06265649 — intervention group
Intervention type: OTHER
Intervention: NOM
Description: Non-operative management (NOM) for ALCD consists of lab test monitoring, fluid therapy, antibiotic therapy, abscess drainage if >4cm, restoring a regular diet
Study NCT06336824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tab. Trimethoprim-sulfamethoxazole, Tab. Clindamycin, Tab. Cephalexin, or Tab. Linezolid
Description: The choice of study drug will depend on the susceptibility of the respective isolate, expected drug interactions, contraindications, and expected side effects.~Investigators will assess whether the first-choice regimen can be given and then consider the alternative regimen. The antibiotics can be switched from first choice to the respective alternative medications during the intervention period if clinically necessary. The route of administration must be maintained according to the randomized group.
Study NCT06336824 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Cloxacillin, IV Cefazolin, IV Vancomycin, or IV Ceftaroline
Description: The choice of study drug will depend on the susceptibility of the respective isolate, expected drug interactions, contraindications, and expected side effects.~Investigators will assess whether the first-choice regimen can be given and then consider the alternative regimen. The antibiotics can be switched from first choice to the respective alternative medications during the intervention period if clinically necessary. The route of administration must be maintained according to the randomized group.
Study NCT05090410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: filgotinib 200mg/day
Description: Patients will be randomized in a 1:1 ratio to the administration of filgotinib 200mg/day or subcutaneous tocilizumab 162mg/biweekly switched from MTX ± other csDMARDs throughout the study period.
Study NCT05090410 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: subcutaneous tocilizumab 162mg/biweekly
Description: Patients will be randomized in a 1:1 ratio to the administration of filgotinib 200mg/day or subcutaneous tocilizumab 162mg/biweekly switched from MTX ± other csDMARDs throughout the study period.
Study NCT05634590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Description: 4mg, orally, once daily, 3 weeks on/ 1 week off
Study NCT05634590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: Irinotecan 180 mg/m2, and LV 400 mg/m2 followed by bolus 5-fluorouracil 400mg/m2 and a 46-48h continuous infusion 2400mg/m2 5-fluorouracil on day 1, q2w
Study NCT05634590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6
Description: Oxaliplatin 85 mg/m2, and LV 400 mg/m2 followed by bolus 5-fluorouracil 400mg/m2 and a 46-48h continuous infusion 2400mg/m2 5-fluorouracil on day 1, q2w
Study NCT05524272 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: This study aims to evaluate the effects of colour by number mandala in decreasing the stress of children hospitalized due to their chronic disease.
Description: Colour by number Mandala in different sizes includes pictures and numbers. The child has to find the colour specified in the number and colour it with the specified colour. Colourful pictures emerge as a result of colouring
Study NCT04217902 — intervention group
Intervention type: OTHER
Intervention: Description of patients' experiences of diabetes care delivery and planning
Description: Semi-directed interviews will be conducted with people living with type 1 or type 2 diabetes in person or by phone to assess and describe the care delivery pathway they have been through. Information on 3 domains will be assessed: clinical (information they consider essential for health care professionals to systematically have access to during consultations and other health-related interventions such as therapeutic education sessions), technological (what kind of digital services and technologies they use or are willing to use), and behavioural (the decision-making process and the key interactions that build the care delivery pathway).
Study NCT04217902 — intervention group
Intervention type: OTHER
Intervention: Description of health care professionals needs and experiences in diabetes care delivery and planning
Description: Semi-directed interviews will be conducted with health care professionals working in diabetes care in person or by phone to assess and describe their needs and experiences in diabetes care. Information on 3 domains will be assessed: clinical (the information they consider to be essential to inform decisions in diabetes care, where and if they currently find that information and problems they might encounter), technological (which software they currently use and how data is input into clinical information systems), and behavioural (how care coordination is currently managed, how interactions with patients and other professionals are undertaken).
Study NCT06403267 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NoNO-42
Description: a single dose sterile 20 ml vial containing lyophilized powder for reconstitution containing 300 mg of NoNO-42 active ingredient.
Study NCT06403267 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 ml 0.9% normal Saline
Study NCT05076682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Choline
Description: Choline 300mg tid or 500mg bid, p.o
Study NCT05076682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-PD-1 antibody and chemotherapy
Description: PD-1 antibody SHR1210 200mg q2w chemotherapy (whether and which should be given depends on the treatment regimen before enrollment)
Study NCT05076682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Cromoglicate
Description: Sodium Cromoglicate will be administered intranasally (nasal spray) (5 spray each nostril 4 times a day, 1 mg/spray)
Study NCT04975789 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: InfoViz
Description: The pain InfoViz tool is a two-page paper tool that consists of an explanation of how to use the tool in both Hmong and English, a culturally-appropriate Faces pain severity scale, pain body diagram, and 13 pain qualities in the form of icons representing each pain quality metaphor. The interpreter explains the instructions in Hmong, then marks the body areas corresponding to the location of pain reported by the participant, and marks the pain qualities expressed by the metaphors selected by the Hmong patient. In the clinic appointment, the interpreter communicates to the physician, in English, the pain location and qualities identified by the participant, using the medical terms identified on the InfoViz tool.
Study NCT05173051 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Solid Medication intake vs. crushed medication intake
Description: The swallowing ability for solid and crushed medications in stroke patients is evaluated.
Study NCT05076682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: Efavirenz 600mg qd, p.o
Study NCT06348576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-209
Description: PO, Once daily(QD), 8weeks
Study NCT06348576 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AD-2091
Description: PO, Once daily(QD), 8weeks
Study NCT06348576 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AD-209 Placebo
Description: PO, Once daily(QD), 8weeks
Study NCT04721509 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental : Smartphone-based telemedicine with the app 'Songaree diabetes'
Description: Experimental group: outpatient clinic and offline education every 12 weeks plus telemedicine and education with smartphone app 'Songaree diabetes' every 2 weeks for 24 weeks
Study NCT05036694 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: FUJILAM KIT
Description: Urine based test to detect LAM
Study NCT04941716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Given PO
Study NCT06348576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-2091 Placebo
Description: PO, Once daily(QD), 8weeks
Study NCT06217432 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training for knee extensors
Description: The exercise will be started at 60% of 1 repetition maximum (RM) and progressed to 75% of 1 RM during the first 3 weeks and maintained throughout the intervention period. The exercise will be performed slowly (6 s/ repetition).
Study NCT04941716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study NCT04941716 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT04941716 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration and biopsy
Study NCT04941716 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow aspiration and biopsy
Study NCT04941716 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT04941716 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT05663892 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Biktarvy 50/200/25 Tab
Description: As the HIV ART, the combination of B/F/TAF, known as Biktarvy®, which is a widely available Single Tablet Regimen (STR) approved by Health Canada is the drug under investigation. Participants in groups 1 and 2 will either have to already be taking B/F/TAF or will be required to switch to it at baseline and they will self-administer B/F/TAF once daily in the morning, with or without food. Participants taking their dosage at night will be required to switch to a morning dose at the screening visit.
Study NCT05663892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biktarvy 50/200/25 Tab
Description: As the HIV ART, the combination of B/F/TAF, known as Biktarvy®, which is a widely available Single Tablet Regimen (STR) approved by Health Canada is the drug under investigation. Participants in groups 1 and 2 will either have to already be taking B/F/TAF or will be required to switch to it at baseline and they will self-administer B/F/TAF once daily in the morning, with or without food. Participants taking their dosage at night will be required to switch to a morning dose at the screening visit.
Study NCT05663892 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol Tablets
Description: Oral 17(beta)-estradiol as the estrogen and an anti-androgen (pharmaceutical \[e.g., spironolactone, cyproterone, finasteride, leuprolide, bicalutamide, dutasteride\] and/or surgical \[orchiectomy\] and/or medical \[hypogonadism\]).Doses of estradiol range from 1 mg to a maximum of 6 mg per day.~Participants must take 2 mg until the Month 2 Visit. Trans women participants in both groups 1 and 3 must divide their dose to twice a day (BID) if they are taking > 2 mg per day and take 2 mg in the morning and the rest of the dosing in the evening. Participants who are only taking 2mg of estradiol once daily at night must switch their dosing to the morning. Participants who either crush or take the oral estradiol sublingually must switch to swallowing the tablet orally from the day after the screening visit until the Month 2 visit, otherwise the estradiol concentrations will be markedly higher.
Study NCT05663892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol Tablets
Description: Oral 17(beta)-estradiol as the estrogen and an anti-androgen (pharmaceutical \[e.g., spironolactone, cyproterone, finasteride, leuprolide, bicalutamide, dutasteride\] and/or surgical \[orchiectomy\] and/or medical \[hypogonadism\]).Doses of estradiol range from 1 mg to a maximum of 6 mg per day.~Participants must take 2 mg until the Month 2 Visit. Trans women participants in both groups 1 and 3 must divide their dose to twice a day (BID) if they are taking > 2 mg per day and take 2 mg in the morning and the rest of the dosing in the evening. Participants who are only taking 2mg of estradiol once daily at night must switch their dosing to the morning. Participants who either crush or take the oral estradiol sublingually must switch to swallowing the tablet orally from the day after the screening visit until the Month 2 visit, otherwise the estradiol concentrations will be markedly higher.
Study NCT06485518 — intervention group
Intervention type: BEHAVIORAL
Intervention: The 5G RHS group receiving audio-video conferencing and effective data management for decision-making via augmented reality platform RealHealthcare System.
Description: The 5G RHS group will receive audio-video conferencing and effective data management for decision-making via augmented reality platform. A total of 14 physicians from SRRSH will be participated in the study, offering remote consultations and instant guidance to the physician.
Study NCT05828784 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Intersomatic arthrodesis
Description: Arthrodesis is an operative modality also used in the treatment of multiple recurrences of herniated discs, stenosis (narrowing) of the spinal anal, degenerative and malformative spondylolisthesis.~The procedure can be performed with different surgical techniques, but in all cases it aims to achieve the same goal: to re-establish, through the use of spacers, the correct distance between two vertebral somes, in cases of disc degeneration, that are no longer able to fulfill their function; that is, they no longer absorb mechanical stresses and/or compress the nerve structures of the spine causing almost always unbearable (disabling) pain.
Study NCT05656313 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Measures of speech intelligibility in a noisy situation with speech from the side and from behind (measured with CC-OLSA Test)
Description: The Concurrent OLSA test (CC-OLSA) is a speech recognition test with three turn-taking talkers presenting sentences of the Oldenburg sentences test at fixed signal-to-noise ratios.~CC-OLSA is the only one-talker-at-a-time speech test that is sensitive at the desired SNR and uses sentences with an intelligibility function with slopes of 10-17 %/dB.
Study NCT05656313 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Measures of speech intelligibility in a noisy situation with speech from the side and from behind (measured with CC-OLSA Test)
Description: The Concurrent OLSA test (CC-OLSA) is a speech recognition test with three turn-taking talkers presenting sentences of the Oldenburg sentences test at fixed signal-to-noise ratios.~CC-OLSA is the only one-talker-at-a-time speech test that is sensitive at the desired SNR and uses sentences with an intelligibility function with slopes of 10-17 %/dB.